Earnings Feed
Start Free
Maze Therapeutics, Inc.·4

Mar 3, 4:20 PM ET

Bachrodt Amy 4

4 · Maze Therapeutics, Inc. · Filed Mar 3, 2026

Insider Transaction Report

Form 4
Period: 2026-03-02
Maze Therapeutics, Inc.MAZE
Bachrodt Amy
SVP, Finance
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-03-02$10.42/sh+5,000$52,100→ 17,965 total
  • Sale

    Common Stock

    [F1][F2]
    2026-03-02$44.44/sh−1,300$57,774→ 16,665 total
  • Sale

    Common Stock

    [F1][F3]
    2026-03-02$45.47/sh−3,700$168,237→ 12,965 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1][F4]
    2026-03-02−5,000→ 36,333 total
    Exercise: $10.42Exp: 2034-12-08→ Common Stock (5,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F5]
    2026-03-02+32,000→ 32,000 total
    Exercise: $45.61Exp: 2036-03-01→ Common Stock (32,000 underlying)
  • Award

    Restricted Stock Units

    [F6][F7][F8]
    2026-03-02+16,000→ 16,000 total
    → Common Stock (16,000 underlying)
Footnotes (8)
  • [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
  • [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.01 to $44.91 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
  • [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.03 to $45.99 per share, inclusive.
  • [F4]The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
  • [F5]The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date.
  • [F6]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
  • [F7]The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date.
  • [F8]These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.
Signature
/s/ Courtney Phillips, as attorney-in-fact|2026-03-03

Documents

1 file
  • 4
    form4-03032026_090334.xmlPrimary